| HOME >> MEDICINE >> TECHNOLOGY |
$
.48$
.81$
.99$
.35 Diluted
$
.45$
.71$
.92$
.19 Weighted-average ordinary shares used in computing net income per share: Basic
56,95241,20955,43740,788 Diluted
60,55446,60159,31946,238 JAZZ PHARMACEUTICALS PLC SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended June 30,Six Months Ended June 30,2012201120122011Xyrem
$
89,097$ 56,178$ 162,534$
98,956Erwinaze/Erwinase (1)
6,007-6,007-Prialt (1)
5,555-15,077-Psychiatry:Luvox CR
10,4717,28620,02914,411FazaClo LD (1)
5,956-11,535-FazaClo HD (1)
3,362-5,922-Other (1)
7,862-14,542-Total
$ 128,310$ 63,464$ 235,646$ 113,367(1)
Net sales for the three and six months ended June 30, 2012 reported by Jazz Pharmaceuticals plc include net sales from the historic Azur Pharma business for the period from April 1, 2012 through June 30, 2012 and from January 18, 2012 through June 30, 2012 and net product sales from the historic EUSA Pharma business for the period from June 12, 2012 through June 30, 2012.The following unaudited pro forma information represents the combined net product sales for the three and six months ended June 30, 2012 and 2011, respectively, as if the merger with Azur Pharma and the acquisition of EUSA Pharma had each been completed on January 1, 2011: SUMMARY OF PRODUCT SALES, NET (PRO FORMA) (In thousands) (Unaudited) Three Months Ended June 30,Six Months Ended June 30,2012201120122011Xyrem
$ 89,097$ 56,178$ 162,534$ 98,956Erwinaze/Erwinase
32,8888,88265,79516,048Prialt
5,5554,96915,4179,843Psychiatry:Luvox CR
10,4717,28620,02914,411FazaClo LD
'/>"/>
| SOURCE Jazz Pharmaceuticals plc Copyright©2012 PR Newswire. All rights reserved |